Management of Human Rhinovirus/Enterovirus Infections
For rhinovirus and enterovirus infections, treatment is primarily supportive and symptomatic, as no effective antiviral therapy is currently available or recommended for routine clinical use. 1
Clinical Context and Disease Spectrum
Rhinovirus (HRhV)
- Most common cause of upper respiratory tract infections (rhinorrhea, postnasal drip, cough) with occasional tracheobronchitis 1
- Incubation period: approximately 1.9 days
- Generally benign, self-limiting course in immunocompetent hosts
- Lower respiratory tract disease with frank pneumonia occurs in <10% of immunocompromised patients (particularly allogeneic HSCT recipients), with estimated mortality <10% 1
Enterovirus (HEnV)
- Can cause severe disease including meningoencephalitis, myelitis, paralysis, myocarditis, sepsis-like syndrome, respiratory disease, and acute hepatitis 2
- Most common cause of viral meningitis 2
- Specific types (EV-A71, EV-D68) associated with outbreaks and significant morbidity/mortality 2
- EV-A71: hand-foot-mouth disease with rare severe rhomboencephalitis
- EV-D68: severe respiratory disease and acute flaccid myelitis
Treatment Approach
Standard Management
The role of treatment is fundamentally limited by the lack of effective antiviral agents and supporting clinical trials 1. Current management consists of:
- Symptomatic and supportive care only 3, 4
- Oxygen therapy as needed (continuous oxygen, high-flow nasal cannula, or mechanical ventilation for severe cases) 5
- Monitoring for complications, particularly in high-risk populations
No Recommended Antiviral Therapy
- No general recommendation for antiviral treatment can be made 1
- Pleconaril (viral capsid-binding inhibitor) showed promise in trials but is not approved for clinical use 4
- Ribavirin and IVIG lack supporting evidence for rhinovirus/enterovirus infections 1
Antibiotic Considerations
Antimicrobial agents should NOT be routinely prescribed as they are not active against viruses, and inappropriate use contributes to antimicrobial resistance 4. Recent data shows declining antibiotic use (60% to 48.9%) without adverse outcomes 6.
High-Risk Populations Requiring Closer Monitoring
Immunocompromised Patients
- Allogeneic HSCT recipients: highest risk for progression to lower respiratory tract disease 1
- Lymphopenia <500/µL: risk factor for LRTID in HSCT patients 1
- Myeloablative conditioning increases pneumonia risk 1
Pediatric Populations
- Children 0-15 years have 1.5× higher risk of RV/EV infection 7
- 8× higher risk with RSV coinfection 7
- Underlying chronic diseases increase risk of severe complications (ARDS, septic shock) 5
Chronic Respiratory Disease
- 2.5× increased risk of asthma exacerbation (OR 2.545) 7
- 1.8× increased risk of COPD exacerbation (OR 1.781) 7
Diagnostic Considerations
Diagnosis relies on RT-PCR targeting the 5' noncoding region for sensitivity and rapid turnaround 2. For suspected neurological infections, obtain:
- Respiratory samples (nasopharyngeal swab)
- Stool samples
- CSF and blood samples
This multi-site sampling is critical because viruses like EV-D68 are rarely detectable in CSF or stool 2.
Key Clinical Pitfalls
- Avoid routine antibiotic prescription - these are viral infections
- Don't assume mild disease in immunocompromised patients - monitor closely for progression to LRTID
- Recognize coinfections are common (19% with other respiratory viruses) but don't typically worsen outcomes in immunocompetent hosts 1, 6
- Asymptomatic shedding occurs in 13% of HSCT patients with prolonged shedding >4 weeks 1